ESMO 2019

Breast Cancer

Triple negative breast cancer gets positive news: KEYNOTE-522 interim results

Presented By

Prof. Peter Schmid, Queen Mary University of London, UK

Trial

Phase 3, KEYNOTE-522

Conference

ESMO 2019

26 November, 2019 23:12

CDK4/6 inhibitors change landscape of breast cancer treatment: 2 studies

Expert

Prof. George Sledge (Stanford University School of Medicine, USA), Prof. Nadia Harbeck (University of Munich, Germany)

Trial

Monaleesa-3, Monarch 2

Conference

ESMO 2019

26 November, 2019 22:03

Veliparib-chemo combo prolongs survival without disease progression in some advanced breast cancer patients

Presented By

Veronique Diéras, Centre Eugène Marquis, Rennes, France

Trial

Phase 3, BROCADE 3

Conference

ESMO 2019

26 November, 2019 14:04

Lung Cancer

Improved response rates without survival benefit with pembrolizumab in pretreated mesothelioma

Expert

Dr Sanjay Popat, Royal Marsden Hospital NHS Foundation Trust, UK

Trial

PROMISE-meso

Conference

ESMO 2019

26 November, 2019 23:04

Frontline ipilimumab/nivolumab improves OS in advanced NCLSC

Presented By

Prof. Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Trial

Phase 3, CheckMate-227

Conference

ESMO 2019

26 November, 2019 22:05

First-line osimertinib significantly lengthens OS in NSCLC

Presented By

Prof. Suresh Ramalingam, Emory University, Atlanta, USA

Trial

FLAURA

Conference

ESMO 2019

26 November, 2019 21:05

Liquid biopsy to decide the best treatment for NSCLC

Presented By

Dr Shirish Gadgeel (University of Michigan, USA)

Trial

Phase 2, BFAST

Conference

ESMO 2019

26 November, 2019 14:05

Melanoma

Long-term data from CheckMate 067

Presented By

Prof. James Larkin (Royal Marsden NHS Foundation Trust, London, UK)

Trial

Phase 3, CheckMate 067

Conference

ESMO 2019

26 November, 2019 23:06

Adjuvant nivolumab provides benefit

Presented By

Prof. Jeffrey S. Weber (NYU Langone Medical Center, New York City, USA)

Trial

Phase 3, CheckMate 238

Conference

ESMO 2019

26 November, 2019 22:15

Nivolumab+ipilimumab superior to monotherapy for melanoma brain metastases

Expert

Prof. Georgina Long, Melanoma Institute Australia, Sydney, Australia

Trial

ABC

Conference

ESMO 2019

26 November, 2019 14:15

GI Cancers

Preoperative chemotherapy for colon cancer

Presented By

Prof. Dion Morton (University of Birmingham, UK)

Trial

FOxTROT

Conference

ESMO 2019

26 November, 2019 23:20

Nivolumab improves OS in advanced oesophageal cancer

Presented By

Prof. Byoung Chul Cho (Yonsei University College of Medicine, South Korea)

Trial

Phase 3, ATTRACTION-3

Conference

ESMO 2019

26 November, 2019 22:19

Liquid biopsy identifies relapse in patients with colorectal cancer after surgery

Presented By

Prof. Julien Taieb (Hopital European Georges Pompidou, France)

Trial

Phase 3, IDEA-FRANCE

Conference

ESMO 2019

26 November, 2019 21:17

In hepatocellular carcinoma, CheckMate 459 misses OS endpoint, but some interesting trends emerge

Expert

Dr Arndt Vogel (Hannover Medical School, Germany)

Trial

Phase 3, CheckMate 459

Conference

ESMO 2019

26 November, 2019 20:21

Heavily pre-treated GIST: ripretinib improves PFS

Presented By

Prof. Margaret von Mehren (Fox Chase Cancer Center, USA)

Trial

Phase 3, INVICTUS

Conference

ESMO 2019

26 November, 2019 19:21

FGFR2+ cholangiocarcinoma: pemigatinib active as second-line treatment

Presented By

Prof. Antoine Hollebecque (Gustave Roussy Cancer Center, France)

Trial

Phase 2, FIGHT-202

Conference

ESMO 2019

26 November, 2019 18:21

IDH1+ cholangiocarcinoma: phase 3 results show improved PFS

Presented By

Dr Ghassan Abou-Alfa (Memorial Sloan-Kettering Cancer Center, New York, USA)

Trial

Phase 3, ClarIDHy

Conference

ESMO 2019

26 November, 2019 17:22

Advanced colorectal cancer and BRAF mutations: triplet combination improves survival

Presented By

Prof. Scott Kopetz (MD Anderson Cancer Center, Houston, USA)

Trial

Phase 3, BEACON CRC

Conference

ESMO 2019

26 November, 2019 14:22

Genitourinary Cancers

Gynaecological Cancers

Ovarian cancer patients benefit from combined maintenance therapy

Presented By

Prof. Isabelle Ray-Coquard (Université Claude Bernard, Lyon, France)

Trial

Phase 3, PAOLA-1/ENGOT-ov25

Conference

ESMO 2019

26 November, 2019 23:25

Combination of PARP inhibition plus chemotherapy in ovarian cancer

Presented By

Robert Coleman (University of Texas, MD Anderson Cancer Center, Houston, USA)

Trial

Phase 3, VELIA

Conference

ESMO 2019

26 November, 2019 22:26

PFS benefit with niraparib as first-line maintenance in ovarian cancer

Presented By

Prof. Antonio González Martín (Clinica Universidad de Navarra, Spain)

Trial

Phase 3, PRIMA/ENGOT-OV26/GOG-3012

Conference

ESMO 2019

26 November, 2019 14:26

CNS Tumours

Ceritinib in ALK+ NSCLC brain metastases

Presented By

Dr Laura Quan Man Chow (University of Texas at Austin, USA)

Trial

Phase 2, ASCEND-7

Conference

ESMO 2019

26 November, 2019 23:28

Adding bevacizumab to temozolomide-based therapy in neuroblastoma

Trial

Phase 2, BEACON-Neuroblastoma

Conference

ESMO 2019

26 November, 2019 14:29

Solid tumours/pan-tumour data

Mixed data: AMG 510 in tumours with KRASG12C

Presented By

Prof. Ramaswamy Govindan (Washington University, St Louis, USA)

Conference

ESMO 2019

26 November, 2019 23:30

DNA profiling of carcinoma of unknown primary should inform treatment

Presented By

Prof. Karim Fizazi (University of Paris Sud, France)

Trial

GEFCAPI 04, CUPISCO

Conference

ESMO 2019

26 November, 2019 22:30

Larotrectinib: safe and effective in TRK fusion-positive tumours

Presented By

Dr David Hyman (Memorial Sloan Kettering Cancer Center, New York, USA)

Trial

SCOUT, NAVIGATE

Conference

ESMO 2019

26 November, 2019 14:30